期刊
PEDIATRIC BLOOD & CANCER
卷 50, 期 6, 页码 1271-1273出版社
WILEY-LISS
DOI: 10.1002/pbc.21391
关键词
malignant pheochromocytoma; MIBG therapy; neuroblastoma; sialoadenifis
资金
- NCI NIH HHS [P01CA106450] Funding Source: Medline
Radioiodinated metaiodobenzylguanidine [I-131-MIBG] is commonly used to treat resistant neuroblastoma or metastatic pheochromocytoma [MP] with little non-hematopoietic toxicity. We describe here transient sialoadenitis, a previously unreported complication. Ten patients [9 neuroblastoma and 1 MP] received 12-18 mCi/kg of I-131-MIBG. Five patients had bilateral parotid swelling, two with associated buccal discomfort within 24 hr of injection which subsided within 48 hr. Grade 3 or 4 serum amylase elevation was documented in 8/8 patients tested [median 1,336; range: 5768,830 U/L] which normalized [25-125 U/L] within 4-14 [median 5.5] days. Serum lipase remained normal. Patients did not develop subsequent dry mouth or dysphagia.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据